CTLA4 and glioma: The efficient delivery of ICIs to the glioma is expected to directly disrupt the PD-1/PD-L1 or CTLA-4/B7-1 complex formation in the tumor, resulting in the activation of brain local immune response and leading to the improved survival of glioma mice [26].